Vireo Growth (VREOF) Profit After Tax (2020 - 2026)
Vireo Growth (VREOF) reported Profit After Tax of -$20.3 million for Q1 2026, down 212.31% on a YoY basis from $18.1 million in Q1 2025, and little changed sequentially from -$20.4 million in Q4 2025.
Vireo Growth (VREOF) Profit After Tax (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Profit After Tax data on file, last reported at -$20.3 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 212.31% year-over-year to -$20.3 million; the trailing twelve-month figure through Mar 2026 stood at -$81.9 million (down 194.66% YoY), and the FY2025 full-year result was -$68.1 million, down 143.2% from the prior year.
- Profit After Tax held at -$20.3 million in Q1 2026, from -$20.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$668411.0 in Q2 2024 to a low of -$26.3 million in Q3 2025.
- A 5-year average of -$10.8 million and a median of -$8.4 million in 2023 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax soared 90.88% in 2024 and sank 2134.26% in 2025, its largest moves.
- Tracing VREOF's Profit After Tax over 5 years: stood at -$13.3 million in 2022, then soared by 65.5% to -$4.6 million in 2023, then sank by 242.61% to -$15.7 million in 2024, then dropped by 29.75% to -$20.4 million in 2025, then gained by 0.35% to -$20.3 million in 2026.
- Business Quant data shows VREOF's Profit After Tax at -$20.3 million in Q1 2026, -$20.4 million in Q4 2025, and -$26.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 369.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -20.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.30 Mn |
| Dec 31, 2025 | -20.37 Mn |
| Sep 30, 2025 | -26.30 Mn |
| Jun 30, 2025 | -14.93 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | -4.93 Mn |
| Jun 30, 2024 | -668,411.00 |
| Mar 31, 2024 | -6.71 Mn |
| Dec 31, 2023 | -4.58 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -7.33 Mn |
| Mar 31, 2023 | -8.41 Mn |
| Dec 31, 2022 | -13.28 Mn |
| Sep 30, 2022 | -8.42 Mn |
| Jun 30, 2022 | -6.18 Mn |
| Mar 31, 2022 | -14.57 Mn |
| Dec 31, 2021 | -12.93 Mn |
| Sep 30, 2021 | -6.87 Mn |
| Jun 30, 2021 | -7.01 Mn |